BNTC (Benitec Biopharma Inc. Common Stock)

Insider Trading Activity

Every open-market purchase and sale reported by BNTC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Form 4 Filings
49
most recent
Open-Market Buys
11
code P
Sales
0
code S
Reporting Insiders
6
current holders
BNTC — Recent Form 4 Transactions (latest 2026-05-28)
FiledInsiderRole TypeSharesValue
2026-05-28 David Matthew Friedman Director A
2026-01-26 Sharon Mates Director A
2025-12-29 Aaron Cowen 10%+ Owner Buy
2025-12-22 Averill Madison Master Fund, Ltd. Director Buy
2025-12-03 Edward F Smith Director A
2025-12-03 Peter Francis Director A
2025-12-03 J KEVIN BUCHI Director A
2025-12-03 Kishan Mehta Director A
2025-12-03 Sharon Mates Director A
2025-11-20 Sophie Mukadam Chief Operating Officer A
2025-11-20 Megan Boston Chief Financial Officer A
2025-11-20 Jerel A. Banks Chief Executive Officer A
2025-11-10 Averill Madison Master Fund, Ltd. Director Buy
2025-11-07 Sharon Mates Director A
2025-04-02 Averill Madison Master Fund, Ltd. Director Buy
2025-03-28 SUVRETTA CAPITAL MANAGEMENT, LLC Director Buy
2025-03-13 J KEVIN BUCHI Director G
2025-03-03 J KEVIN BUCHI Director M
2024-12-26 SUVRETTA CAPITAL MANAGEMENT, LLC Director Buy
2024-12-11 Edward F Smith Director A
2024-12-11 Megan Boston Executive Director A
2024-12-11 J KEVIN BUCHI Director A
2024-12-11 Peter Francis Director A
2024-12-11 Jerel A. Banks Chief Executive Officer A
2024-12-11 Kishan Mehta Director A
2024-12-05 Aaron Cowen 10%+ Owner Buy
2024-11-21 SUVRETTA CAPITAL MANAGEMENT, LLC Director Buy
2024-09-30 SUVRETTA CAPITAL MANAGEMENT, LLC Director X
2024-03-08 Jerel A. Banks Chief Executive Officer A
2024-03-08 Megan Boston Executive Director A
2023-12-07 Edward F Smith Director A
2023-12-07 J KEVIN BUCHI Director A
2023-12-07 Peter Francis Director A
2023-08-14 J KEVIN BUCHI Director Buy
2023-08-14 Megan Boston Executive Director Buy
2023-06-15 Jerel A. Banks Chief Executive Officer A
2023-06-15 Megan Boston Executive Director A
2022-12-09 Peter Francis Director A
2022-12-09 Edward F Smith Director A
2022-12-09 J KEVIN BUCHI Director A
2021-12-10 Peter Francis Director A
2021-12-10 Edward F Smith Director A
2021-12-10 J KEVIN BUCHI Director A
2021-12-09 Steven Michael Oliveira 10%+ Owner Buy
2020-12-11 Megan Boston Executive Director A
2020-12-11 J KEVIN BUCHI Director A
2020-12-11 Peter Francis Director A
2020-12-11 Jerel A. Banks Chief Executive Officer A
2020-12-11 Edward F Smith Director A
BNTC — Current Insider Holders
InsiderRole Shares HeldValue
Director 9,546,875
Director 8,793,245
10%+ Owner 1,836,569
Director 103,910
10%+ Owner 55,971
Chief Financial Officer 25,927
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the BNTC quote page; the site-wide leaderboard is on the insider transactions hub.